Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Arcturus Therapeutics Faces Setback in Cystic Fibrosis mRNA Therapy Trial

Arcturus Therapeutics, a San Diego-based biopharmaceutical company, has encountered a significant obstacle in its pursuit of an innovative mRNA therapy for cystic fibrosis (CF). The company's stock plummeted by 55% following the release of disappointing interim data from its phase 2 trial of ARCT-032, an inhaled mRNA treatment for CF patients with Class I mutations.

NoahAI News10/23/2025

Terns Pharmaceuticals Discontinues Obesity Drug TERN-601 After Disappointing Phase II Results

Terns Pharmaceuticals has announced the discontinuation of its oral GLP-1 drug TERN-601 following underwhelming results in a mid-stage clinical trial. The California-based biotech company made the decision after the drug showed both lackluster efficacy and concerning safety signals in its Phase II study for obesity treatment.

NoahAI News10/22/2025

Alector Discontinues Dementia Drug Development, Announces Restructuring

Alector, a clinical-stage biopharmaceutical company, has announced the discontinuation of its investigational antibody latozinemab following disappointing results from the Phase III INFRONT-3 trial. The drug, which was being developed for a genetic form of frontotemporal dementia (FTD), failed to demonstrate clinical benefit in patients with FTD caused by progranulin gene mutations.

NoahAI News10/22/2025

Sanofi's Efdoralprin Alfa Shows Promise in Phase 2 Trial for Alpha-1 Antitrypsin Deficiency

Sanofi's $1.7 billion investment in the rare disease space has yielded encouraging results, as its drug candidate efdoralprin alfa demonstrated superiority over the current standard of care in a phase 2 trial for alpha-1 antitrypsin deficiency (AATD) emphysema. The study's positive outcomes position Sanofi to engage with regulators about the next steps in the drug's development pathway.

NoahAI News10/22/2025

Ipsen Acquires ImCheck Therapeutics in €1 Billion Deal, Boosting Oncology Pipeline

French pharmaceutical company Ipsen has announced its acquisition of ImCheck Therapeutics, a next-generation immuno-oncology biotech, in a deal worth up to €1 billion. The acquisition, expected to close by the end of Q1 2026, centers on ImCheck's lead clinical-stage program for acute myeloid leukemia (AML) and reinforces Ipsen's commitment to expanding its oncology portfolio.

NoahAI News10/22/2025

Biotech Markets Show Signs of Recovery, but Experts Urge Caution

The biotech industry is witnessing a resurgence, with multiple market indicators trending positively after years of recalibration. However, industry experts warn against premature celebration, suggesting that this may be the new normal rather than a full-fledged comeback.

NoahAI News10/22/2025

Pharmaceutical Industry Shaken by Leadership Changes, Regulatory Decisions, and Clinical Advances

In a week of significant developments, the pharmaceutical industry has seen major shifts in corporate leadership, regulatory decisions, and clinical trial results. From boardroom shake-ups to promising cancer treatments, these events are poised to shape the sector's landscape in the coming months.

NoahAI News10/22/2025

Takeda's $11.4 Billion Deal with Innovent Biologics Marks Major Oncology Push

Takeda Pharmaceutical has entered into a landmark agreement with Chinese biotech firm Innovent Biologics, securing rights to two promising cancer candidates in a deal worth up to $11.4 billion. This strategic move positions Takeda to bolster its oncology pipeline and prepare for the post-Entyvio era.

NoahAI News10/22/2025

Boston Scientific Reports Strong Q3 Growth, Acquires Nalu Medical

Boston Scientific, a leading medical device manufacturer, has reported robust third-quarter results and announced a significant acquisition, demonstrating continued growth and expansion in the medical technology sector.Boston Scientific's third-quarter revenue surpassed $5 billion, marking a 20.3% year-over-year increase. This growth, while impressive, represents a slight deceleration from the second quarter's 22% rise. The company's performance was driven by strong results across its diverse portfolio of medical devices.

NoahAI News10/22/2025

Takeda's $11 Billion Bet on Chinese Cancer Drugs Signals Industry Shift

Takeda Pharmaceutical Company has announced a landmark collaboration with Chinese biotech firm Innovent Biologics, potentially worth over $11 billion. This deal marks a significant pivot towards China's burgeoning pharmaceutical sector and underscores the growing trend of major pharmaceutical companies seeking innovative oncology treatments from Chinese laboratories.

NoahAI News10/22/2025

Electra Therapeutics Secures $183M in Series C Funding for Rare Disease Drug Development

Electra Therapeutics, a San Francisco-based biotech company, has announced a successful $183 million Series C funding round to advance its innovative drug development program for secondary hemophagocytic lymphohistiocytosis (HLH), a rare and potentially fatal inflammatory condition. The funding will support further clinical testing of the company's lead drug candidate, ELA026, which targets signal regulatory proteins (SIRPs) to treat this severe immune disorder.

NoahAI News10/22/2025

Flagship Pioneering Launches AI-Powered Expedition Medicines with $50M Investment

Flagship Pioneering, a prolific company creator in the biotech sector, has unveiled its latest venture into artificial intelligence-driven drug discovery with the launch of Expedition Medicines. The new company, backed by a $50 million investment from Flagship, aims to revolutionize small molecule therapies by targeting previously "undruggable" proteins.

NoahAI News10/22/2025

«1...12 13 14...67 »